Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

July 1, 2019

Conditions
Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

rituximab

IV

DRUG

bendamustine

IV

DRUG

lenalidomide

PO

Trial Locations (17)

50266

Mercy Medical Center-West Lakes, West Des Moines

50309

Iowa Methodist Medical Center, Des Moines

Iowa Oncology Research Association CCOP, Des Moines

Medical Oncology and Hematology Associates-Des Moines, Des Moines

50314

Medical Oncology and Hematology Associates, Des Moines

Mercy Medical Center - Des Moines, Des Moines

50316

Iowa Lutheran Hospital, Des Moines

50325

Medical Oncology and Hematology Associates-West Des Moines, Clive

Mercy Cancer Center-West Lakes, Clive

51104

Mercy Medical Center-Sioux City, Sioux City

St. Luke's Regional Medical Center, Sioux City

55905

Mayo Clinic, Rochester

58501

Mid Dakota Clinic, Bismarck

Saint Alexius Medical Center, Bismarck

Sanford Bismarck Medical Center, Bismarck

51101-1733

Siouxland Hematology-Oncology, Sioux City

50266-7700

Methodist West Hospital, West Des Moines

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Celgene Corporation

INDUSTRY

lead

Alliance for Clinical Trials in Oncology

OTHER